Teachers Insurance & Annuity Association of America acquired a new position in shares of Bristol-Myers Squibb (NYSE:BMY) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 7,000 shares of the biopharmaceutical company’s stock, valued at approximately $428,000.
Other hedge funds have also recently modified their holdings of the company. Delphi Private Advisors LLC bought a new stake in shares of Bristol-Myers Squibb in the 4th quarter valued at about $108,000. Atlantic Trust LLC bought a new stake in shares of Bristol-Myers Squibb in the 2nd quarter valued at about $111,000. Massey Quick Simon & CO. LLC grew its position in shares of Bristol-Myers Squibb by 523.5% in the 3rd quarter. Massey Quick Simon & CO. LLC now owns 1,777 shares of the biopharmaceutical company’s stock valued at $113,000 after buying an additional 1,492 shares during the last quarter. NuWave Investment Management LLC bought a new stake in shares of Bristol-Myers Squibb in the 4th quarter valued at about $119,000. Finally, Horan Capital Advisors LLC. acquired a new position in shares of Bristol-Myers Squibb in the 3rd quarter valued at about $122,000. Institutional investors and hedge funds own 71.51% of the company’s stock.
BMY stock opened at $60.88 on Friday. Bristol-Myers Squibb has a fifty-two week low of $51.56 and a fifty-two week high of $70.05. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.43 and a current ratio of 1.55. The company has a market cap of $101,726.25, a P/E ratio of 20.70, a PEG ratio of 1.62 and a beta of 0.96.
Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings results on Monday, February 5th. The biopharmaceutical company reported $0.68 earnings per share for the quarter, topping analysts’ consensus estimates of $0.67 by $0.01. Bristol-Myers Squibb had a return on equity of 35.43% and a net margin of 4.85%. The business had revenue of $5.45 billion for the quarter, compared to the consensus estimate of $5.35 billion. During the same period in the prior year, the business earned $0.63 EPS. The firm’s revenue for the quarter was up 3.9% on a year-over-year basis. equities research analysts forecast that Bristol-Myers Squibb will post 3.22 earnings per share for the current year.
The company also recently declared a quarterly dividend, which will be paid on Tuesday, May 1st. Investors of record on Friday, April 6th will be paid a dividend of $0.40 per share. This represents a $1.60 dividend on an annualized basis and a yield of 2.63%. The ex-dividend date of this dividend is Thursday, April 5th. Bristol-Myers Squibb’s dividend payout ratio (DPR) is currently 53.16%.
A number of research analysts have recently issued reports on BMY shares. Argus reissued a “buy” rating and issued a $66.43 price objective (down from $75.00) on shares of Bristol-Myers Squibb in a research note on Wednesday, March 21st. Vetr downgraded Bristol-Myers Squibb from a “hold” rating to a “sell” rating and set a $60.72 price objective on the stock. in a research note on Tuesday, January 16th. Zacks Investment Research raised Bristol-Myers Squibb from a “sell” rating to a “hold” rating in a research note on Friday, January 19th. JPMorgan Chase set a $75.00 price objective on Bristol-Myers Squibb and gave the company an “overweight” rating in a research note on Tuesday, March 20th. Finally, Credit Suisse Group set a $62.00 price objective on Bristol-Myers Squibb and gave the company a “hold” rating in a research note on Monday, January 22nd. Three investment analysts have rated the stock with a sell rating, eleven have given a hold rating and ten have assigned a buy rating to the company’s stock. Bristol-Myers Squibb presently has an average rating of “Hold” and an average target price of $66.68.
TRADEMARK VIOLATION WARNING: This piece of content was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece of content on another site, it was illegally copied and reposted in violation of U.S. and international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/04/07/teachers-insurance-annuity-association-of-america-takes-position-in-bristol-myers-squibb-bmy.html.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in the various therapeutic classes, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus (HIV) infection.
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.